Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Short Interest Update

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) saw a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 126,080 shares, an increase of 424.7% from the July 15th total of 24,029 shares. Currently, 5.3% of the shares of the company are short sold. Based on an average daily volume of 6,655,441 shares, the days-to-cover ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Wall Street Zen downgraded shares of Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Weiss Ratings began coverage on shares of Lakewood-Amedex Biotherapeutics in a research note on Monday, July 20th. They set a “sell (e-)” rating for the company. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Lakewood-Amedex Biotherapeutics Trading Up 0.4%

LABT stock traded up $0.01 during trading on Wednesday, reaching $2.37. 63,842 shares of the company were exchanged, compared to its average volume of 1,339,024. The firm’s 50 day moving average is $3.63. Lakewood-Amedex Biotherapeutics has a 52-week low of $1.66 and a 52-week high of $98.20. The stock has a market cap of $5.62 million and a P/E ratio of -1.19.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last issued its quarterly earnings data on Friday, May 22nd. The company reported ($2.00) earnings per share (EPS) for the quarter. Equities analysts expect that Lakewood-Amedex Biotherapeutics will post 2.52 earnings per share for the current fiscal year.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.